Bionomics is a fully integrated, international drug discovery and development company creating new therapies that serve large unmet needs in cancer and central nervous system (CNS) disorders. Based in Adelaide, Australia with operations in San Diego, USA and a wholly owned subsidiary in Strasbourg, France, Bionomics is listed on the Australian Securities Exchange (ASX) under the code BNO, and the US OTCQX market under the code BNOEF.

ASX Announcements

  • Full Year Statutory Accounts

    20 August 2019

    Download PDF

  • Bionomics 2018/2019 Preliminary Final Results

    20 August 2019

    Download PDF

  • Bionomics Receives Further R&D Tax Incentive Refund for FY2018 of $1.3M

    22 July 2019

    Download PDF

LATEST CORPORATE PRESENTATION

Latest Analyst Report